1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Moody's Ratings raised Alliance Laundry Holdings' corporate family rating to B1 from B2 and upgraded its senior secured first lien revolving credit facility and term loan to B1 from B2. The company said the upgrade reflects its deleveraging and steady growth, and that borrowing costs on its term loan will fall 25 basis points together with a prior S&P Global Ratings upgrade.
Moody's corporate family rating upgraded to B1 from B2
Senior secured first lien revolving credit facility and term loan also upgraded to B1 from B2
Term loan borrowing costs to decrease 25 basis points, per the company, reflecting this and the prior S&P Global upgrade
Neurogene released updated Phase 1/2 results for its NGN-401 gene therapy in females with Rett syndrome, reporting 47 developmental milestones gained across 10 participants with follow-up of 12 to 30 months. The company reported no plateau or loss of milestones and no new treatment-related serious adverse events since its October 2025 data cutoff. The filing contains clinical data only, with no financial results or guidance changes, and topline results from the Embolden registrational trial are expected in the second half of 2027.
47 total developmental milestones gained across 10 participants, an average of 4.7 per participant, as of the June 16, 2026 data cutoff
Follow-up ranged from 12 to 30 months, with no plateau observed and no milestones lost
No new treatment-related serious adverse events reported since the October 2025 data cutoff; no treatment-related SAEs or DLTs in Embolden as of June 16, 2026
Embolden registrational trial dosing is complete with 25 participants; topline results expected in 2H 2027
On June 28, 2026, Iridium agreed to merge with Rocket Lab, which will acquire all outstanding Iridium common stock for $27.00 in cash plus Rocket Lab shares per Iridium share. The companies put the notional value at $54.00 per share and the enterprise value at approximately $8.0 billion, and the deal requires an Iridium stockholder vote, antitrust clearance, and FCC consent. Iridium would owe Rocket Lab a $223.62 million termination fee in specified circumstances, and its shares would be delisted from Nasdaq if the deal closes.
Each Iridium share receives $27.00 in cash plus Rocket Lab stock; the exchange ratio is fixed at 0.4000 if the Rocket Lab price is $67.50 or less and at 0.2400 if it is $112.50 or more.
The transaction is expected to close in mid-2027, with an outside date of June 28, 2027, extendable to December 28, 2027.
Iridium would pay Rocket Lab a $223.62 million termination fee under specified circumstances, including if its board withdraws its recommendation.
Rocket Lab has received commitments for a $3.6 billion 364-day senior secured bridge term loan from Deutsche Bank and Wells Fargo.
BioCryst said its board approved on June 25, 2026 a plan to discontinue internal discovery programs and close its Birmingham, Alabama facility, with the work substantially complete by the end of 2026. The company cannot yet estimate the total cost of the plan and will file an amendment once it does, while lowering its 2026 non-GAAP operating expense guidance and reaffirming revenue guidance.
Board approved the plan on June 25, 2026; implementation expected to be substantially complete by the end of 2026.
Total costs of the plan are not yet estimated; expected costs include contract, lease and employee termination and severance.
2026 non-GAAP operating expense guidance lowered to $420 million to $440 million from $450 million to $470 million.
Total 2026 revenue guidance of $635 million to $660 million is reaffirmed; ORLADEYO oral pellets expected to be available in early August 2026.
Atlas Lithium said the Minas Gerais permitting commission voted on June 26, 2026 to grant its expansion permit, applied for on November 25, 2024, and the decision was published in the state gazette on June 27, 2026. The permit covers additional mining areas and authorizes assembling and operating its lithium processing plant, processing mined ore there, and selling the lithium concentrate it produces, which the company says positions it to advance its Neves Project.
Permitting commission vote granting the expansion permit: June 26, 2026
Official gazette publication in Minas Gerais, Brazil: June 27, 2026
Permit covers additional mining areas beyond those in the operational permit received October 25, 2024
Permit authorizes plant assembly and operation, ore processing, and sale of lithium concentrate
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.